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Introduction
Choroideremia (CHM, OMIM 303100) is a chorioretinal dystrophy, with an incidence of  1 in 50,000–
100,000, characterized by the progressive degeneration of  photoreceptors (PR), retinal pigment epithelium 
(RPE), and choroid (1, 2). Affected male patients typically suffer from nyctalopia in the first decade of  life 
that progresses to severe peripheral field loss with complete blindness in late adulthood, with no reports of  
associated systemic features (3). CHM is an X-linked recessive, monogenic disorder caused by mutations 
in the CHM gene (OMIM 303390). CHM encodes Rab escort protein 1 (REP1), an essential component 
of  the catalytic Rab geranyl-geranyl transferase II (GGTase II) complex, which is essential for prenylation 
of  Rab GTPase proteins (4, 5). Protein prenylation is a type of  posttranslational lipid modification, which 
involves the covalent addition of  either farnesyl- or GG-pyrophosphate (FPP or GGPP) to proteins via 3 
different prenyltransferases: farnesyltransferase (FTase) and GGTase I and II (4). REP1 and its isoform 
REP2 recruit newly synthesized Rab GTPase proteins and present them to GGTase II, forming a tight 
catalytic complex in which 2 GGPP are transferred onto the C terminus. After prenylation, REP1/2 escorts 
the Rabs to their respective target membranes (6).
Since CHM is ubiquitously expressed, the possibility of  systemic manifestations has long been con-
sidered but remains unproven. It is accepted that REP2 compensates for the REP1 deficiency, providing 
adequate prenylation of  Rab proteins in all extraretinal tissues (7). Lack of  this compensatory mechanism 
in the retina, due to preferential binding affinity of  Rab27a, -6, -8, and -11 to REP1, is thought to lead to 
the accumulation of  these unprenylated Rabs, resulting in an isolated ocular phenotype (5). However, an 
Choroideremia (CHM) is an X-linked recessive chorioretinal dystrophy caused by mutations in 
CHM, encoding for Rab escort protein 1 (REP1). Loss of functional REP1 leads to the accumulation 
of unprenylated Rab proteins and defective intracellular protein trafficking, the putative cause for 
photoreceptor, retinal pigment epithelium (RPE), and choroidal degeneration. CHM is ubiquitously 
expressed, but adequate prenylation is considered to be achieved, outside the retina, through the isoform 
REP2. Recently, the possibility of systemic features in CHM has been debated; therefore, in this study, 
whole metabolomic analysis of plasma samples from 25 CHM patients versus age- and sex-matched 
controls was performed. Results showed plasma alterations in oxidative stress–related metabolites, 
coupled with alterations in tryptophan metabolism, leading to significantly raised serotonin levels. 
Lipid metabolism was disrupted with decreased branched fatty acids and acylcarnitines, suggestive of 
dysfunctional lipid oxidation, as well as imbalances of several sphingolipids and glycerophospholipids. 
Targeted lipidomics of the chmru848 zebrafish provided further evidence for dysfunction, with the use of 
fenofibrate over simvastatin circumventing the prenylation pathway to improve the lipid profile and 
increase survival. This study provides strong evidence for systemic manifestations of CHM and proposes 
potentially novel pathomechanisms and targets for therapeutic consideration.
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online self-reporting survey of  190 individuals — CHM male patients (n = 117), female carriers (n = 53), 
and unaffected males (n = 20) — undertaken by Zhou et al. suggested a higher prevalence of  diabetes, 
high cholesterol, and hyperglycemia in CHM male patients, but these differences were not significant after 
age adjustment (8). They suggested that hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibi-
tors (also known as statins) for the treatment of  hypercholesterolemia may have a negative effect on the 
visual function of  CHM patients (8). GGPP and FPP are both isoprenoids produced through the meva-
lonate pathway, which is the main pathway for cholesterol synthesis and the target of  these drugs (9). 
It has recently been reported that statins lead to lower pools of  both isoprenoids necessary for GGTase 
activity and consequent inhibition of  both farnesyl and GG prenylation (10–13).
Previously, analysis of lipid contents from blood samples of 5 CHM patients uncovered systemic fatty acid 
(FA) abnormalities in both plasma and RBCs. Specifically, lower levels of eicosenoic acid (C20:1[n-9]), erucic 
acid (C22:1[n-9]), and docosadienoic acid (C22:2[n-6]) were found in the plasma, with elevation of tridecae-
noic acid (C13:1), myristolenic acid (C14:2), and octacosanoic acid (C28:0). RBCs revealed increased levels 
of capric acid (C10:0), nervonic acid (C24:1[n-9]), and plasmalogen derivative dimethylacetal acid (16:0), as 
well as a decrease in eicosenoic acid (C20:1[n-9]) (14). A follow-up report refuted these findings, stating that no 
lipid abnormalities were detected in the plasma of 9 CHM patients, nor could crystal deposits be detected after 
transmission and scanning electron microscopy analyses of WBCs and RBCs, respectively (15).
Herein, we performed whole metabolomic profiling of  blood plasma from 25 CHM male patients and 
25 age- and sex-matched controls to identify metabolic alterations in CHM and to gain insights into any 
systemic involvement. Several pathways were significantly altered in the disease cohort, including sphingo-
lipid signal transduction, oxidative stress, and serotonin production.
Zebrafish have been acknowledged as a valuable model for studying metabolism and metabolic diseases 
(16, 17). Accordingly, targeted lipidomics analysis of  the CHM zebrafish model chmru848, with a C>T nonsense 
variant (p.[Gln32*]) in chm exon 2 on chromosome 21, confirmed lipid and sphingolipid alterations found in 
humans. Furthermore, we also undertook survival studies and lipidomic analysis of  chmru848 embryos treated 
with simvastatin or fenofibrate (a fibric acid derivative mediated via activation of  PPARα) to explore if  pre-
nylation is affected by statins. Zebrafish possess only 1 rep isoform, which leads to retinal degeneration from 
4.5 days postfertilization (dpf) and multisystemic disease resulting in embryonic lethality by 5–6 dpf (18, 19).
This study discovers the metabolomic signature in CHM and identifies putative disease biomarkers, 
which may be critical to the future development of  disease-modifying or preventative therapies.
Results
Patient description. Detailed clinical and genetic evaluation of  25 male CHM patients is included in Sup-
plemental Table 1 (supplemental material available online with this article; https://doi.org/10.1172/jci.
insight.146934DS1). Mean ± SD age of  CHM patients at the time of  blood collection was 40.6 ± 11.4 
years (range 20–63 years), with no significant difference with the control group (40.7 ± 12.3 years, P = 
0.938). Analysis of  the food frequency questionnaire (FFQ) revealed no significant dietary differences 
between disease and control groups with regard to average consumption of  food and drink over the past 
12 months (Supplemental Table 2).
Global metabolite differences between CHM patients and controls. In total, 817 compounds of  known identity 
were detected in the blood plasma matrix of  CHM patients and controls. Principal component analysis 
(PCA) of  CHM patient and healthy control samples revealed largely overlapping grouping with no clear dis-
tinction between study groups (Figure 1A). Consistently, hierarchical cluster analysis of  the data set revealed 
the same trend, with interdigitated sample clustering for healthy control and CHM patient samples (Figure 
1B). Welch’s 2-sample t test (2 tailed) was used to identify compounds that differed significantly between 
CHM and healthy control study groups, with 85 named compounds achieving statistical significance (P ≤ 
0.05) and a further 48 approaching significance (0.05 < P < 0.10).
Individual biochemicals can differentiate between CHM patients and control study groups. Random forest (RF) 
analysis indicated high probability that individual metabolites can distinguish between study groups, with a 
predictive accuracy of 86%. The top 30 metabolites based on distinguishing CHM from control groups are 
represented in Figure 1C and in more detail in Supplemental Table 3. These include several sphingolipid signal 
transducers (sphingosine, sphingadienine, sphinganine, hexadecasphingosine [d16:10], sphinganine 1-phos-
phate, and sphingosine 1-phosphate [S1P]); stearoyl-glycerophosphoserine (GPS) moieties for both lysolip-
ids (e.g., 1-stearoyl-GPS [18:0]); and phosphatidylserine (PS) derivatives (e.g., 1-stearoyl-2-arachidonoyl-GPS 
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[18:0/20:4] and 1-stearoyl-2-oleoyl-GPS [18:0/18:1]). Additionally, several metabolites in the cysteine pathway 
(cysteine s-sulfate, cysteine, cysteinylglycine, cys-gly oxidized) were highlighted (Figure 1C).
Pathway set enrichment analysis to elucidate the metabolic pathways affected between CHM patients 
and controls revealed significant perturbation of  multiple networks, including oxidative stress, tryptophan 
metabolism, hemoglobin metabolism, and sphingolipid and lipid metabolisms (Figure 1D).
CHM patients exhibit evidence of  increased oxidative stress. We observed mixed perturbations in the cysteine 
pathway (Figure 2A), such as loss of  cysteine (fold change [FC] 0.81, P < 0.001) (Figure 2B) and associated 
dipeptide cysteinylglycine (FC 0.56, P < 0.001) (Figure 2C), as well as methionine sulfone (FC 0.80, P < 
Figure 1. Global metabolo-
mic analysis of choroidere-
mia (CHM) patients versus 
age- and sex-matched 
controls. (A) Principal 
component analysis (PCA). 
Control and CHM samples 
are represented as blue and 
red circles, respectively (n = 
25 each group). (B) Cluster 
analysis of control and 
CHM samples show no clear 
separation between groups. 
(C) Top 30 metabolites 
detected by random forest 
analysis based on impor-
tance to group separation. 
(D) Pathway analysis cal-
culated using MetaboLync 
pathway analysis (MPA) 
software. Pathways with 
MPA score higher than 1 
were considered.
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0.05) (Figure 2F), which combined may indicate an increased demand for the antioxidant glutathione. An 
elevation of  oxidative stress marker cys-gly oxidized (FC 1.35, P < 0.01) (Figure 2E) and increase of  lipid 
oxidation marker 12,13-DiHOME (FC 1.31, P < 0.05) (Figure 2I) were also observed, coupled with an 
accumulation of  hypotaurine (FC 1.53, P < 0.01) (Figure 2H) and a trend increase in 5-oxoproline (FC 1.08, 
P < 0.1) (Figure 2G). Several other known antioxidants were found in significantly lower levels in CHM 
samples, like bilirubin (FC 0.80, P < 0.05) (Figure 3I), indolepropionate (FC 0.40, P < 0.05) (Figure 3E), 
β-cryptoxanthin (provitamin A) (FC 0.69, P < 0.05), urate (FC 0.87, P < 0.05), and suspected antioxidant 
3-(3-hydroxyphenyl)propionate (FC 0.42, P < 0.005) (data not shown). Cysteine-s-sulfate is an incompletely 
Figure 2. CHM patients exhibit evidence of increased oxidative stress. (A) Schematic of the glutathione metabolism 
pathway, where several compounds were found to be increased (red) or decreased (green) in CHM patients compared 
with controls. Metabolites trending to significance (0.05 < P ≤ 0.1) are represented in a lighter shade to distinguish from 
those significantly altered (P ≤ 0.05). (B–I) Scatter dot plots of specific metabolites indicating the mean ± SD levels 
in CHM patient samples (red) and control samples (blue) (n = 25). P value was determined using matched pair t tests. 
#0.05 < P ≤ 0.1, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.
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characterized metabolite generated by reaction of  cysteine and inorganic sulfite, and it was greatly reduced 
in CHM plasma (FC 0.10, P < 0.001) (Figure 2D). This likely relates to increased sulfite oxidase (SO) 
activity, which catalyzes the oxidation of  sulfite to sulfate, the potentiation of  which may divert from cyste-
ine-s-sulfate production (Figure 2A). Combined, these observations seem to point to a deficient management 
of  oxidative stress in CHM patients, possibly through deregulation of  gluthathione metabolism, although 
glutathione levels are not usually detected in plasma.
Figure 3. Alterations in tryptophan and hemoglobin metabolism pathways in CHM patients. (A) Pathway schematics 
and altered metabolites in tryptophan metabolism with decreased metabolites in green and increased in red. (B–E) Scat-
ter dot plots of altered metabolites showing control (blue) and CHM (red) groups with mean ± SD (n = 25). (F) Schematic 
representation in the hemoglobin/heme metabolism pathway with decreased metabolites shown in green and increased 
metabolites in red. (G–J) Scatter dot plots of altered metabolites showing control (blue) and CHM (red) groups with mean 
± SD (n = 25). P value was determined using matched pair t tests. #0.05 < P ≤ 0.1, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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CHM patients display alterations in tryptophan metabolism. The tryptophan metabolism pathway was enriched 
in this study, with a pathway enrichment score of 1.62, where a score greater than 1 indicated that the path-
way contained a higher number of experimentally regulated compounds relative to the overall study in CHM 
patients relative to controls (Figure 1D and Figure 3A), with serotonin levels being strikingly elevated in CHM 
patients (FC 3.82, P < 0.001) (Figure 3B). Serotonin is an important monoaminergic neurotransmitter that reg-
ulates stress response, sleep, and behavior, among other body functions, and this increase indicates that trypto-
phan metabolism appears to be strongly shifted toward monoamine production. This observation is consistent 
with lower levels of alternative tryptophan catabolic pathways, involving microbiome-related indolelactate (FC 
0.79, P < 0.05) and indolepropionate (FC 0.40, P < 0.05) in CHM patients (Figure 3, D and E). Also, there was 
no significant difference in nicotinamide levels between CHM and control samples (FC 1.02, P = 0.96) (not 
shown), although higher levels of quinolate (FC 1.45, P < 0.05) were detected (Figure 3C).
Defects in cytochrome activity. Hemoglobin synthesis and porphyrin metabolism pathway showed a high 
pathway enrichment score of  6.67 in this study (Figure 1D). Although only 6 compounds were analyzed 
overall (Figure 3F), we observed significantly lower levels of  bilirubin isomers (Z, Z) (FC 0.82, P < 0.05) 
(Figure 3I), (E, Z or Z,E) (FC 0.82, P < 0.05) and (E, E) (FC 0.79, P < 0.05) (not shown), coupled to a 
trending reduction of  its precursor biliverdin (FC 0.87, P < 0.1) in CHM samples (Figure 3H). In contrast, 
the product of  bilirubin reduction, L-urobilin, was detected in higher levels (FC 2.53, P < 0.01) (Figure 3J). 
However, levels of  heme were not significantly increased (FC 1.58, P > 0.1) (Figure 3G), suggesting that 
alterations occur downstream in the pathway.
While altered levels of  bilirubin and urobilin could indicate increased heme breakdown in CHM 
patients, broader evidence may indicate lower liver cytochrome P450 activity. Cytochrome P450s metab-
olize several methylxanthines, which largely trend lower in CHM individuals, such as 3, 7-dimethylurate 
(FC 0.62, P < 0.05), 3-methylxanthine (FC 0.59, P < 0.1), caffeic acid sulfate (FC 0.61, P < 0.1), 7-methy-
lurate (FC 0.48, P < 0.1), theobromine (FC 0.63, P < 0.1), and 7-methylxanthine (FC 0.60, P < 0.1) (data 
not shown). Additionally, cytochrome P450s also catalyze steroid biosynthesis, and a trending decrease in 
several steroid hormones and related metabolites in CHM patients was observed (Supplemental Figure 1), 
which further supports the hypothesis of  impaired cytochrome activity in CHM patients.
CHM patients exhibit disruption in sphingolipid metabolism. Deeper analysis of  the compounds identified by 
RF analysis revealed broader perturbation of  the sphingolipid pathways in CHM patients (Figure 4). The 
sphingolipid pathway generates the bioactive lipid metabolite ceramide. Ceramides can be produced or uti-
lized through 3 main pathways; de novo biosynthesis, sphingomyelinase (SMase) pathway, or via the salvage 
pathway (Figure 4A). We observed increased levels of  3-phosphoglycerate (FC 1.56, P < 0.01) (Figure 4B), 
a key component to initiate the de novo sphingolipid synthesis, along with several intermediates including 
sphinganine (FC 1.41, P < 0.001) (Figure 4C) and sphinganine 1-phosphate (FC 1.35, P < 0.001) (Figure 4D).
In the salvage pathway, S1P was significantly increased (FC 1.24, P < 0.01) (Figure 4F), as well as hexa-
decasphingosine (d16:1) (FC 1.32, P < 0.01) (Figure 4E). S1P is cleaved into hexadecanal, a fatty aldehyde, 
and phosphoethanolamine; the latter also increased in CHM patients (FC 1.40, P < 0.01) (Figure 4G). 
Although hexadecanal was not detected in this study, its product, hexadecanoic acid (also called palmitic 
acid or palmitate), was not significantly altered in CHM patients (not shown).
A modest depletion of  a number of  sphingomyelins (SMs) was detected including SM(d18:1/20:0, 
d16:1/22:0) (FC 0.91, P < 0.05) (Figure 4H) and SM(d18:1/22:1, d16:1/24:1) (FC 0.92, P < 0.05) (Figure 
4I). SMs are synthesized by the transfer of  a phosphorylcholine residue from phosphatidylcholine (PC) to 
a ceramide by SM synthase. SMs can also be hydrolyzed back to release ceramides and phosphorylcholine 
residues by the action of  SMase (20). In accordance, several PC were also detected in significantly lower 
levels in CHM patients, such as PC(16:0/22:6) (FC 0.88, P < 0.05) and PC(18:1/22:6) (FC 0.87, P < 0.05) 
(data not shown), implying phospholipid deregulation caused by REP1 deficiency.
Ceramide is considered the central molecule in the sphingolipid metabolic pathway. Surprisingly, none 
of  the ceramides detected in this study showed significantly altered levels in CHM samples compared with 
controls (not shown). Overall, these results could suggest a compensatory mechanism, possibly mediated 
by REP2, to regulate the ceramide pool through an increase of  both de novo and salvage pathways to pos-
sibly compensate for the underperformance of  the SMase pathway.
CHM patients exhibit broader alterations in lipid metabolism. Sphingolipid metabolism also contributes to 
glycerophospholipid metabolism, and disruption of  this pathway can reduce glycerolipid levels, leading to 
broader lipid metabolism alterations. We observed differential effects of  glycerolipid subclasses, with lower 
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levels of  PC intermediates (Figure 5A) but increased levels of  phosphatidylethanolamine (PE) (Figure 
5B) and PS lipids (Figure 5C). Of  the latter group, 2 PS intermediates — 1-stearoyl-GPS(18:0) and 1-stea-
royl-2-arachidonoyl-GPS(18:0/20:4) — were particularly increased in CHM patients, with nearly 4- and 
6-FC compared with control samples, respectively (Figure 5C).
No major differences were found in CHM patients regarding long-chain FA levels, in contrast with the 
study from Zhang et al. (14). However, reduced levels of  branched FAs 17-methylstearate (i19:0) (FC 0.75, 
P < 0.05) and 15-methylpalmitate (i17:0) (FC 0.78, P < 0.1) were observed, as well as several dicarboxylic 
FAs (DCFAs) (Figure 5D) and acylcarnitines (Figure 5E). Combined, these results point to impaired lipid 
oxidation in CHM patients.
Figure 4. Disturbance of sphingolipid metabolism in CHM patients. (A) General sphingolipid metabolism pathway with compounds differentially detected 
in CHM patients highlighted in red (increased) or green (decreased) compared with control levels. (B–I) Scatter dot plots of key metabolite levels in both 
control (blue) and choroideremia (red) plasma samples. Lines indicate mean ± SD (n = 25). P value was determined using matched pair t tests. *P ≤ 0.05, 
**P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. SM, sphingomyelin.
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Human CHM lipid alterations are recapitulated in chmru848 zebrafish. LC-MS–based lipid profiling of chmru848 
homozygous mutant zebrafish embryos at 6 dpf further corroborated the alterations in lipid metabolism detect-
ed in the plasma of CHM patients. Lipidomic-based PCA showed a clear separation between WT and chmru848 
groups, which was not visible in the human analysis (Figure 6A). Twelve compounds were found with differ-
ential levels between chmru848 and WT samples that were also in the top 30 biochemicals from the human study, 
such as Lyso-PS (18:0) (1-stearoyl-GPS) and sphingosine (d18:1/22:0) (lactosyl-N-behenoyl-sphingosine). These 
metabolites were increased in both human and zebrafish CHM models (Figure 6, B and C). Metabolites found 
in significantly lower levels in chmru848, as well as in human CHM samples, included SM(d16:1/22:0) (Figure 6F) 
and several PC compounds — i.e., PC(16:0/22:6), PC(18:0/18:2), and PC(18:1/22:6) (Figure 6, G–I).
S1P (Figure 6D), bilirubin (Figure 6E), SM(d16:1/24:1), and SM (d18.2/22:0) (not shown) were detected in 
chmru848, but levels were not statistically significant compared with WT samples. In contrast, carnitine (C18-DC) 
(Figure 6J) and diacylglycerol (DG[16:0/16]) (Figure 6K) were significantly increased and decreased, respective-
ly, in chmru848, while the same compounds had opposite trends in the human study (0.05 < P ≤ 0.1) (Figure 5E, 
not shown). These differences are likely due to the presence of a single REP isoform in zebrafish, resulting in 
complete loss of REP activity, compared with humans, which have the compensatory action of REP2.
Simvastatin versus fenofibrate treatment in chmru848.  Since the lipid profile in both humans and zebrafish with 
CHM show disruption, the effect of HMG-CoA reductase inhibitors (also known as statins) and fibric acid 
derivatives (fibrates) were investigated using the zebrafish model. Statins have been shown to block the meva-
lonate pathway necessary for cholesterol synthesis, the same pathway necessary to produce isoprenoids essen-
tial for prenylation and REP1 function (9). Therefore, in an already compromised system, we wanted to inves-
tigate if  fibrates (whose mode of action circumvents the mevalonate pathway) would be safer compounds to 
Figure 5. Metabolites involved in lipid 
metabolism subclasses differentially 
detected in CHM patients. (A–E) Bars 
represent mean ± SD of control (blue) and 
choroideremia (red) plasma samples (n = 25). 
P value was determined using matched pair 
t tests. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, 
****P ≤ 0.0001. #0.05 < P ≤ 0.1. GPC, glyc-
erophosphocholine; GPE, gylcerophosphoe-
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aid in normalizing lipid dysregulation without exacerbating the underlying biochemical genetic defect in CHM 
and potentially accelerating their retinal phenotype.
We administered predetermined doses of 0.3 nM simvastatin and 700 nM fenofibrate to WT and chmru848 
mutant fish (n = 3, 50 embryos per group) from 24 hours, replenished daily till 9 dpf. There were no adverse effects 
seen in treated WT embryos, all demonstrating normal stereotyped motor behaviors that allowed them to navigate 
their environment, including slow and fast swimming bouts, with no signs of imbalance or lack of movement.
Characterization of untreated and treated chmru848 is presented in Figure 7. Survival studies show that 
untreated mutant zebrafish mean survival was 4.5 ± 0.5 days, while fish treated daily with simvastatin survived 
6.8 ± 0.4 days and those with daily fenofibrate survived 7.8 ± 0.5 days (Figure 7A). Cholesterol levels were 
measured by Amplex Red Cholesterol Assay kit, which suggested a trend increase in mutant compared with 
WT fish (P = 0.032). Simvastatin- and fenofibrate-treated mutants both showed comparable reduction of cho-
lesterol levels compared with untreated fish, although only the fenofibrate-treated group showed a significant 
Figure 6. Lipidomic profiles of zebrafish. (A) PCA of day 6 chm ru848 mutant fish untreated (red squares) or treated with 0.3 nM simvastatin (black squares) 
or 700 nM fenofibrate (gray squares), compared with WT fish (blue circles). (B–K) Scatter dot plots with key metabolites shared with human plasma 
metabolites and respective levels detected in all groups. Lines indicate mean ± SD (n = 4, 10 fish per group). P value was determined using 1-way ANOVA. 
*P ≤ 0.05, **P ≤ 0.01. a.u., arbitrary units; Lyso-PS, lysophosphoserine/1-stearoyl-GPS; Sph(d18:1/22:0), lactosyl-N-behenoyl-sphingosine; S1P, sphin-
gosine-1-phosphate; CAR, carnitine; PC, phosphatidylcholine; SM, sphingomyelin.
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reduction (P = 0.048) (Figure 7B). Histological analysis of chmru848 eyes at 6 dpf showed microphthalmia, cata-
ract, and widespread retinal degeneration with loss of lamination and areas of RPE hypertrophy/atrophy (Fig-
ure 7C). Wholemount analysis of chmru848 embryos showed characteristic systemic defects, including pericardial 
and abdominal oedema, an uninflated swim bladder, and persistent yolk sac (Figure 7C) (21). Following treat-
ment, no obvious phenotypic improvement was detected in simvastatin-treated retinas, while fenofibrate-treat-
ed mutants showed clearer retinal lamination and improved lens structure, although areas with significant RPE 
atrophy were still present (Figure 7C).
We then performed targeted lipidomic analysis of  chmru848 mutant fish treated with 0.3 nM simvastatin 
or 700 nM fenofibrate, compared with untreated mutants and WT fish. PCA results show no clear distinc-
tion between treated groups and untreated chmru848 fish (Figure 6A).
The effect of  simvastatin on chmru848 mutant fish leads to a decrease of  Lyso-PS(18:0) (Figure 6B) and 
PC(18:1/22:6) (Figure 6I), but the remaining metabolites showed no significant changes between simvas-
tatin-treated and untreated groups. Fibrates are PPARα agonist lipid-lowering drugs that seem to have a 
broader effect in lowering overall lipid levels compared with statins (22). Consistently, chm fish treated with 
700 nM fenofibrate showed lower levels of  most compounds selected in this lipidomics analysis compared 
with untreated chmru848 samples — metabolites that were already decreased in untreated mutant samples, par-
ticularly SMs (Figure 6F) and PCs (Figure 6, G–I), and were reduced even further. These compounds were 
largely unchanged by simvastatin, confirming the different modes of  action between the drugs. However, it 
Figure 7. Characterization of chmru848 zebrafish treated daily with 0.3 nM simvastatin or 700 nM fenofibrate from 24 hours after fertilization. (A) Survival 
days of chmru848 fish untreated (red) or treated with simvastatin (black) or fenofibrate (gray) (n = 4, 50 fish per group). (B) Average levels of cholesterol (μM per μg 
of protein) in WT fish (blue circles), and chmru848 zebrafish untreated (red squares) or treated with simvastatin (black squares) or with fenofibrate (gray squares) 
at 6 dpf (n ≥ 2, 5 fish per condition). Data represent mean ± SD. (C) Retinal sections and wholemount morphology of WT, untreated chmru848 fish, and chmru848 
fish treated with simvastatin or fenofibrate at 6dpf. Scale bar: 100 μm. P value was determined using 1-way ANOVA. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. 
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must be mentioned that there was a high variability in fenofibrate-treated chm zebrafish, suggesting that these 
results need further analysis or require a larger sample number to reduce variability and reach significance.
Discussion
This is the first study to our knowledge to explore systemic disturbances in CHM through whole metabolo-
mic analysis of blood plasma from 25 CHM patients and 25 age- and sex-matched controls using ultra high– 
performance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS). Global analysis of the 
metabolomic data identified several biochemicals that can be adopted as biomarkers to distinguish between the 
2 groups, including 1-steroyl-GPS and lactosyl-N-behenoyl-sphingosine. Pathway enrichment analysis high-
lighted significant alterations in CHM patients, the key pathways being lipid metabolism, particularly sphingo-
lipid metabolism, cysteine and glutathione metabolism, tryptophan metabolism, and heme metabolism.
Sphingolipids are involved in different cellular processes and can have opposing effects; ceramides and 
sphinganines are considered proapoptotic and can mediate apoptosis, growth arrest, and senescence. In 
contrast, S1P is associated with cell proliferation, migration, and inflammation, and SMs are linked to cell 
growth and adhesion (20, 23). In the eye, oxidative stress is shown to increase ceramide and sphingosine 
levels, leading to photoreceptor death and RPE degradation, while S1P acts as a mediator of  PR survival, 
preventing PR death during development and when exposed to oxidative stress (24). Analysis of  sphingolipid 
metabolism revealed substantial imbalances in the presumptive ceramide pathway in CHM plasma, with 
increased levels of  several sphinganines and sphingosines, including S1P, in parallel with lower levels of  SMs, 
suggesting compromised ceramide production via the SMase pathway. It is unclear if  these findings correlate 
with the retinal environment and disease severity, but measuring sphingolipid levels in PR and RPE derived 
from CHM patients, such as through generation of  patient-derived induced pluripotent stem cells, may pro-
vide novel information on the effect of  these metabolites in disease pathophysiology.
Sphingolipid metabolism perturbations can also suggest compromised degradation of  the S1P pathway, 
which catalyzes the conversion of  hexadecanal to hexadecanoic acid. Interestingly, this pattern is similar 
to metabolic perturbations identified in Sjögren-Larsson syndrome (SLS) (OMIM 270200), an autosomal- 
recessive, neurocutaneous disease characterized by ichthyosis, mental retardation, and spastic diplegia (25). 
SLS is caused by mutations in the ALDH3A2 gene, which encodes the membrane-bound fatty aldehyde dehy-
drogenase (FALDH), which catalyzes the dehydrogenation of  hexadecanal in the S1P degradation pathway 
(26). FALDH is present in the retina, RPE, and choroid (27), with ocular defects recently identified in SLS 
patients including perifoveal crystalline inclusions, RPE atrophy with lipofuscin granules, retinal thinning, 
and deficient macular pigment (28). Given the similar perturbations between diseases, we hypothesize that 
FALDH could also be a target for REP1, since it also has been found to require prenylation for proper 
localization and function (10). In fact, other aldehyde dehydrogenases, ALDH3B1 and ALDH3B2, are also 
reported to be prenylated, through both farnesylation and geranylgeranylation (29, 30).
Analysis of  specific metabolites related to lipid metabolism pointed to disruption of  different phospho-
lipid classes. For example, while a reduction of  PC intermediates in CHM patients was detected, we also 
observed increased levels of  some PE and particularly high accumulation of  PS lipids. These different phos-
pholipid subclasses are metabolically and structurally similar; PS is synthesized by PS synthases 1 and 2 in the 
endoplasmic reticulum (ER), which exchange serine for choline or ethanolamine in PC or PE, respectively. 
Conversely, PS can be converted to PE by PS decarboxylase (PSD) in the mitochondria (31). These obser-
vations may imply decreased activity of  these enzymes, particularly PSD. Increased PS levels have not been 
associated with any human phenotype to date, but PS are increased in neuronal cells through docosahexae-
noic acid (DHA), inhibiting neuronal cell death (32). However, levels of  DHA in CHM were not significantly 
altered (FC 0.72, P > 0.1). PS can also result from phospholipase A–type enzymatic activity; this is a mas-
sive enzymatic family involved not only in phospholipid remodeling, but also in cholesterol metabolism, cell 
differentiation, maintenance of  mitochondrial integrity, cell proliferation, and cell death (33). Interestingly, 
some phospholipase A enzymes have also been described as essential for RPE survival and regulation of  POS 
phagocytosis (34, 35), and they have been tightly linked to protein prenylation (36).
Unlike Zhang et al., no significant differences in saturated FAs, monounsaturated FAs, or polyun-
saturated FAs were detected in our cohort (14), except for a reduction of  branched FA 17-methylstearate 
(i19:0). These results were in accordance to the study by Radziwon et al., who did not detect FA metabo-
lism differences in a cohort of  9 CHM patients (15). Nervonic acid, the only FA altered in CHM patients in 
both studies, was not detected through UPLC-MS. However, we observed reduced levels of  a few DCFAs, 
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as well as lower levels of  acylcarnitines, which — combined with a trend reduction of  branched FAs — 
may suggest impaired lipid β oxidation.
Through targeted lipidomic analysis, we show that the zebrafish CHM model, chmru848, also presents dis-
tinct lipid profiles to the WT zebrafish. It should be noted that absence of  rep1 in chmru848, coupled with the 
evolutionary lack of  a compensatory rep2 isoform in zebrafish, results in a severe systemic phenotype that 
leads to embryonic lethality by 5–6 dpf. This contrasts with the human form of  the disease, and it may have 
a global influence on the metabolic parameters. However, systemic lipid abnormalities are characterized by 
overall decreased levels of  several PC and SM, which are recapitulated in the CHM patient plasma. Accord-
ingly, 1-steroyl-GPS is significantly increased in chmru848, highlighting this compound as a putative biomarker 
for CHM, although its role and relation to CHM has not been uncovered yet.
Several recent studies have described the inhibitory effect of  statins on the isoprenoid pathway, as well 
as on prenylation of  several Rab proteins, namely Rab7 (10–12). The chmru848 zebrafish model showed a 
trend increase of  cholesterol levels that were reduced following treatment with both statins and fibrates. 
Overall survival was increased in mutant fish treated with either drug; however, the fenofibrate-treated eyes 
showed a mild rescue with increased overall eye size and a less compacted lens. Interestingly, it was sug-
gested that prenylation of  GTP-binding proteins is also necessary for lens homeostasis (37). Coincidently, 
statin (lovastatin) treatment induced cataract formation in cultured rat lenses, which was alleviated by addi-
tion of  GGPP (13), reinforcing the evidence that statins reduce the GGPP pool in the mevalonate pathway, 
making its use less indicated for CHM patients. We can also suggest that rep1 deficiency causes cataract 
formation in fish, likely due to deficient prenylation. Patients with CHM develop posterior subcapsular 
cataracts; however, the cause of  this remains unclear. In retinitis pigmentosa (RP), increased aqueous flare 
(which is related to the amount of  protein present from increased breakdown of  the blood-retinal barrier 
and inflammation) has been found in patients with posterior subcapsular cataracts, potentially suggesting a 
similar inflammatory mechanism in CHM (38, 39). Considering the broad action of  PPARα agonists, the 
mechanism by which fenofibrate treatment potentially reduces cataract formation in the chmru848 embryos 
is not fully understood, but it may be through lowering cholesterol levels, which can cause cataracts when 
disturbed (40). However, simvastatin-treated lenses showed no improvement, although overall cholesterol 
levels were also lower after treatment. It is therefore important to clarify the mechanism of  action of  fenofi-
brate in chmru848 zebrafish, since — considering the improvement of  the ocular phenotype of  mutant fish, as 
well as its overall increased survival and lower cholesterol levels — fenofibrate (and perhaps other PPARα 
agonists) could have some therapeutic potential for CHM.
In 2012, a phase 1/2 trial was initiated (NCT01654562; https://clinicaltrials.gov/ct2/show/
NCT01654562) to examine the short-term effects of  simvastatin on the vision of  CHM male patients, eval-
uated by full-field scotopic threshold testing. The investigators hypothesized that they would see a reversible 
decrease in the dark-adapted vision in participants taking simvastatin; however, this study was terminated 
due to limited enrollment, with only 2 patients recruited. It is unlikely that, over a period of  5 weeks, a 
detectable change in full-field scotopic threshold testing or the other parameters, including microperimetry, 
would be a useful outcome metric. From this study, we would suggest a safer alternative for CHM patients 
would be to take fibrates to reduce cholesterol and overall lipid dysfunction. However, a trial of  statin versus 
fibrate in those requiring treatment could be undertaken over a 12-month period measuring visual function 
parameters to assess for a decline, but numbers of  patients would need to be high to achieve statistical signif-
icance in view of  the intra- and interfamilial variability also seen with this disease.
Alterations in lipid catabolism are often linked to changes in oxidative stress. We observed mixed pertur-
bations in the cysteine pathway that indicate altered demand for glutathione and may reflect a need to manage 
oxidative stress in CHM patients. While glutathione is typically not detected in plasma, loss of  cysteine and 
associated dipeptide cysteinylglycine, as well as accumulation of  hypotaurine are consistent with increased 
glutathione production. Additionally, differential changes in cysteinylglycine and 5-oxoproline support 
engagement of  the glutathione cycle in CHM patients. This is consistent with our previous study showing 
elevated levels of  oxidative stress (superoxide) in the retina of  chmru848 zebrafish mutant embryos (41). Oxida-
tive damage can lead to a number of  chronic diseases such as atherosclerosis, cardiovascular diseases, stroke, 
diabetics, rheumatoid arthritis, cancer, aging, and other degenerative diseases in humans (42). Although we 
were unable to identify clear markers for these diseases in our study, exploring therapies focused on reducing 
oxidative stress levels may be beneficial in reducing any associated risk in CHM. Patient plasma revealed 
decreased levels of  several known antioxidants; therefore, diet supplementation with antioxidant compounds 
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like N-acetylcysteine (NAC) or even modulators of  nuclear factor erythroid 2–related factor 2 (NRF2), the 
master regulator of  antioxidant response, could be of  interest.
Increased oxidative stress may also contribute to CHM ocular manifestations, since it was found to 
cause retinal PR death and RPE atrophy in RP, with a reduction in the reduced to oxidized glutathione 
ratio (GSH/GSSG) in aqueous humor (43). NAC was found to be an effective antioxidant in RP mouse 
models promoting cone survival and function (44), and a recent phase 1 clinical trial FIGUREHT-RP1 
(NCT03999021 and NCT03063021) of  orally administered NAC (maximum tolerated 1800 mg twice a 
day) showed improvement of  both cone function and best-corrected visual acuity (BCVA) (45). As delivered 
orally, NAC may help reduce the oxidative stress in the retina and the plasma of  CHM patients with wider 
systemic benefit than just halting or slowing further sight loss.
Tryptophan metabolism results in the synthesis of  neurotransmitters serotonin and melatonin, and — 
via the kynurenine pathway — produces nicotinamide, which is linked to inflammation and neurotoxicity of  
the CNS. We further examined metabolic markers of  inflammation; however, there was no strong evidence 
of  involvement. Importantly, we observed a striking increase in serotonin levels in CHM patients. Serotonin 
regulates sleep, mood, and behavior and is also the precursor of  melatonin, a powerful antioxidant essential 
for regulation of  circadian rhythm (46). Serotonin is produced in the pineal gland and the gastrointestinal 
tract, but some can be produced in PR as a precursor of  melatonin, whose production is defined by the levels 
of  light captured by the retina. Furthermore, serotonin acts as a neuromodulator in retinal physiology and 
photoreceptor survival (47). Serotonin is catabolized by action of  monoamine oxidase A (MAO-A) and is 
reuptaken by serotonin transporter (SERT); inhibitors of  both enzymes increase serotonin levels and are 
used worldwide as antidepressants (47). Systemic high levels of  serotonin can cause serotonin syndrome, 
characterized by anxiety, muscle tremors or spasms, rapid heartbeat, and high blood pressure (48). Muta-
tions in MAO-A cause X-linked Brunner syndrome (OMIM 300615) which is characterized by increased 
monoamine levels like serotonin, dopamine, and norepinephrine and leads to mild mental retardation, 
aggressive behavior, sleep disorders, and mood swings (49). Although serotonin levels in these syndromes 
are difficult to compare with CHM, it would be important to elucidate the link with elevated serotonin, since 
there may be a subtle propensity for some of  these features.
Serotonin can also regulate insulin secretion. Serotonylation is a posttranslational modification mecha-
nism where transglutaminases add serotonin to the glutamine residues of  GTPases, forming covalent bonds 
for activation of  intracellular processes (50). Rab3a and Rab27, the latter a known target of  REP1-depen-
dent prenylation, are activated via this mechanism in the pancreas, which in turn promotes glucose-mediated 
insulin secretion (51). Interestingly, we observed significantly reduced levels of  microbiome-related indoles, 
particularly indolepropionate, which has antioxidant properties and was recently associated with lower risk 
of  developing type 2 diabetes mellitus (52). No correlation has been reported between CHM and diabetes, but 
these results suggest close monitoring of  patients for insulin insufficiency.
Melatonin levels could not be detected in this study; however, it has recently been hypothesized as a 
potential antioxidant treatment for age-related macular degeneration (AMD), by reducing oxidative stress, 
inflammation, and apoptosis in the retina (53). AMD etiology has been compared with CHM, and recent 
metabolomic studies also revealed mitochondrial deficiency, as well as systemic carnitine and glutamine 
pathway defects (54–56). Furthermore, Laíns et al. showed decreased glycerophospholipids levels, particu-
larly GPC, in AMD plasma samples (56). CHM and AMD may share a common metabolome; hence, the 
possible role of  both serotonin and melatonin in the retina and RPE should be further elucidated, possibly 
opening new therapeutic avenues.
The cytochrome P450 superfamily is a key family of  monooxygenase enzymes involved in metabolism of  
endogenous molecules, such as steroids and FA. Several of  the metabolites that differed between CHM and 
control groups were connected to liver cytochrome activity, including reduced bilirubin and increased urobi-
lin. Since heme levels were not significantly different, activity of  heme oxygenase 1 (HO-1), a rate-limiting 
enzyme of  heme catabolism, may have been impaired. Interestingly, HO-1 was found to be increased after 
mevalonate pathway inhibition using statins in mice macrophages; this change was dependent on prenyla-
tion, since addition of  FPP or GGPP partially reversed this elevation (57).
Aside from the major metabolic perturbations discussed, there were other differentially identified metab-
olites of  interest, such as ornithine, which was significantly increased (1.13-fold) in CHM. Ornithine is pro-
duced in the urea cycle by the splitting off  of  urea from arginine. Mutations in the ornithine aminotransfer-
ase gene (OAT) cause gyrate atrophy (GA) (OMIM 258870), which is characterized by increased ornithine 
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serum levels and has a similar clinical phenotype to CHM, with patients presenting with night blindness and 
progressive chorioretinal atrophy, eventually leading to blindness (58). Ornithine is toxic to the RPE and ret-
ina; thus, lowering dietary intake can delay further retinal degeneration (59). No major systemic phenotypes 
are known to be associated with GA, but the increased ornithine levels in both disease groups suggest a close 
relationship between REP1 and OAT. Patients may benefit from dietary advice to reduce ornithine intake to 
prevent possible disease exacerbation.
Collectively, these results provide potentially novel insights into the systemic derangements in CHM 
that occur due to disruption of  REP1 activity. CHM is unlikely to be an isolated retinal dystrophy due to 
the ubiquitous expression of  REP1. To date, accumulation of  unprenylated Rab proteins is the only disease 
mechanism described in CHM, but this study proposes putative enzymes, such as FALDH, cytochrome 
P450, or monoamine or heme oxygenases, that could be targets of  systemic REP1. The metabolic pertur-
bations must be considered as presymptomatic risk factors for more chronic systemic involvement. Further 
long-term natural history studies are required regarding CHM and aging to determine the prevalence of  
multisystemic manifestations. Therapeutic approaches could be developed for these modifiable risk factors, 
such as repurposing the S1P receptor functional antagonist, fingolimod, to counter the effects of  S1P accu-
mulation in CHM. Use of  in vitro and in vivo CHM disease models will also prove fundamental to establish 
the connection between the compounds described herein and REP1 function, providing pathomechanisms 
in CHM, currently not completely understood.
Methods
Clinical evaluation. Twenty-five unrelated patients under Moorfields Eye Hospital NHS Foundation Trust 
(London, United Kingdom) with clinically diagnosed CHM and molecularly confirmed CHM hemizygous 
mutations were included in this study, together with 25 age- and sex- matched controls. A detailed ocular 
and medical history was taken with comprehensive ophthalmic examination as part of  routine care (Sup-
plemental Table 1). ETDRS BCVA was measured. Patients with a clinical history of  diabetes, hypercholes-
terolemia, or drug history of  taking statins or any other medications were excluded.
Assessment of  dietary intake. All CHM patients and control subjects were asked to complete a FFQ on their 
average consumption of  various foods and drinks over the past 12 months. The validated FFQ comprised a 
list of  147 food items, and participants were asked to indicate their usual consumption from 1 of  9 frequency 
categories ranging from “never or less than once per month” to “6 or more times per day” (60). Individuals 
would have been excluded if  their answers to > 10 items had been left blank, but this was not true for any of  
the participants. Nutrients were calculated using the UK Nutrient Database (61).
Sample collection. Blood plasma samples were collected from nonfasting CHM patients and age- and sex-
matched healthy individuals (n = 25 per group), between 9 a.m. and 11 a.m. Plasma was extracted by cen-
trifuging whole blood at 600g for 15 minutes at room temperature. Extracted plasma samples were aliquoted 
and stored at –80°C. Samples that had not previously been thawed were shipped on dry ice to Metabolon Inc.
Metabolomics analysis. Blood plasma metabolite extractions for UPLC-MS/MS were completed by Metab-
olon Inc., according to the protocol described in Supplemental Methods.
Metabolic pathway networks and analysis. To visualize and analyze small molecules within relevant net-
works of  metabolic pathways, the detected metabolites in CHM patient and healthy control study groups 
were subjected to MetaboLync pathway analysis (MPA) software (www.portal.metabolon.com). Significant-
ly altered pathways were determined by completing pathway set enrichment analysis within MPA software, 
which was determined by the following equation:
No. of  significant metabolites in pathway (k)/total no. of  detected metabolites in pathway (m)/total 
no. of  significant metabolites (n)/total no. of  detected metabolites (N). Thus, significantly altered pathways 
were determined by (k/m)/(n/N).
A pathway impact score greater than 1 indicated that the pathway contained a higher number of  exper-
imentally regulated compounds relative to the overall study in CHM patients relative to controls.
Zebrafish husbandry. The WT AB and chmru848 embryos were generated by natural pair-wise matings of  
identified heterozygous carriers. Embryos were raised at 28.5°C on a 14-hour light/10-hour dark cycle in a 
90 mm petri dish containing aquarium water. The developmental stages are given in hours or days postfer-
tilization (hpf/dpf), according to morphological criteria (62).
Simvastatin and fenofibrate dosing of  zebrafish. For all the dosing, the drugs were prepared in aquarium 
water. The chmru848 mutant embryos were dechorionated at 10 hpf  and treated at 24 hpf  with either 0.3 
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nM simvastatin or 700 nM fenofibrate (63–65). The embryos were treated with a fresh dose of  the drugs 
every 24 hours, and as a positive control, an equal number of  chmru848 mutant embryos was kept in drug-free 
aquarium water. Survival of  mutant larvae was recorded in days; n = 50 for each treatment group.
Cholesterol assay. Whole-body cholesterol was determined using the Amplex Red Cholesterol Assay kit 
(Invitrogen) according to the manufacturer’s instructions. Pools of  5 WT AB and chmru848 embryos per con-
dition were collected and homogenized in sample buffer on ice. Cholesterol concentrations were measured 
using a TECAN microplate spectrofluorometer with an excitation wavelength of  545 nm and an emission 
wavelength of  590 nm. Concentrations were quantified using authentic cholesterol standards (provided in 
the kit) and estimated based on a gradient dilution of  the cholesterol standards.
Retinal histology and wholemount morphology. Retinal and wholemount morphology analyses were per-
formed as previously described (21). All images were edited using ImageJ (NIH).
Lipidomic analysis of  zebrafish. Ten zebrafish were pooled for each sample (with 4 biological samples 
in total). Homogenization to smooth emulsion was achieved by sonication of  each pool in 100 μL water. 
Liquid-liquid extraction of  this emulsion was performed similar to Izzi-Engbeaya et al. (66). In brief, the 
homogenized pool was mixed with isopropanol (IPA) spiked with internal standards 1:4 (v/v) in a micro-
centrifuge tube, incubated at 4°C with shaking at 1400 rpm for 2 hours, followed by centrifugation for 10 
minutes at 3680g at 4°C, and the supernatant was used for injection. LC-MS data were acquired as pre-
viously described (66). Feature extraction from LC-MS lipid positive and negative ion modes spectra was 
performed in XCMS (67) and by in-house scripts.
Lipid annotation was achieved by MS/MS acquisition, followed by matching to in-house and online 
databases. Measurement of  predefined lipid of  interests were detected, integrated, and reported using an 
in-house open source package (https://doi.org/10.5281/zenodo.3523406).
Statistics. Mann-Whitney U tests were used to compare age and dietary variables between patients and 
controls. Metabolite profiles in CHM patients and controls were quantified in terms of  relative abundance 
and median scaled to 1. Following log transformation and imputation of  missing values, if  any, with the 
minimum observed value for each compound imputed, statistical analyses were performed using ArrayStudio 
(Omicsoft) or R version 2.14.2 (https://www.r-project.org/). Metabolite profile distinctions between CHM 
patients and healthy individuals were evaluated by matched pair t tests. An estimate of  the FDR (q value) 
was calculated, and a threshold of  q ≤ 0.10 was used to correct for false discovery of  statistically significant 
compounds. FC was determined by dividing the relative abundance of  each metabolite in the CHM patients 
blood plasma by the relative abundance of  the metabolite in the blood plasma of  healthy control individuals. 
FC values with P ≤ 0.05 and q ≤ 0.10 were considered statistically significant, while FC values with 0.05 < P 
< 0.10 were considered as trending toward significance.
For zebrafish survival and cholesterol measurements, significance was calculated by 1-way ANOVA. For 
lipidomic analysis, means and SDs were calculated using 10 fish per group (n = 4). Statistical analysis was per-
formed by 1-way ANOVA using GraphPad Prism 8 v8.4.2 (GraphPad software; https://www.graphpad.com/).
Multivariate statistical analysis for lipidomic profiling of  zebrafish (i.e., PCA) was based upon the 
XCMS data sets from LC-MS spectra of  zebrafish extracts and was performed using MATLAB based 
PLS_Toolbox version 8.7.1 (2019) (Eigenvector Research Inc.; http://www.eigenvector.com).
Study approval. The study protocol adhered to the tenets of the Declaration of Helsinki and received approval 
from Moorfields Eye Hospital NHS Foundation Trust and the National Research Ethics Committee (REC12/
LO/0141). Written informed consent was obtained from all participants prior to their inclusion in this study.
Zebrafish (WT AB and chmru848) were bred and maintained in the University College London animal 
facility according to standard protocols and the guidelines of  the ARVO Statement for the Use of  Animals in 
Ophthalmic and Vision Research (68).
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